Barry Weiner Net Worth

The estimated Net Worth of Barry W Weiner is at least $2.51 Million dollars as of 14 January 2019. Mr. Weiner owns over 2,226 units of Enzo Biochem stock worth over $1,261,979 and over the last 22 years he sold ENZ stock worth over $0. In addition, he makes $1,251,550 as President and Treasurer at Enzo Biochem.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Weiner ENZ stock SEC Form 4 insiders trading

Barry has made over 4 trades of the Enzo Biochem stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 2,226 units of ENZ stock worth $6,010 on 14 January 2019.

The largest trade he's ever made was exercising 112,500 units of Enzo Biochem stock on 25 October 2017 worth over $337,500. On average, Barry trades about 5,912 units every 93 days since 2002. As of 14 January 2019 he still owns at least 1,136,918 units of Enzo Biochem stock.

You can see the complete history of Mr. Weiner stock trades at the bottom of the page.

Barry Weiner biography

Barry W. Weiner serves as President, Treasurer of the Company. He is the Company’s President and Treasurer as well as a founder of the Company. He has served as the Company’s President since 1996, and previously held the position of Chief Financial Officer until December 2019 and Director until February 2020. He has also previously held the position of Executive Vice President. Before his employment with Enzo Biochem, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a member of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and his Master of Business Administration in Finance from Boston University.

What is the salary of Barry Weiner?

As the President and Treasurer of Enzo Biochem, the total compensation of Barry Weiner at Enzo Biochem is $1,251,550. There are 1 executives at Enzo Biochem getting paid more, with Elazar Rabbani having the highest compensation of $1,487,800.

How old is Barry Weiner?

Barry Weiner is 70, he's been the President and Treasurer of Enzo Biochem since 2020. There are 3 older and 11 younger executives at Enzo Biochem. The oldest executive at Enzo Biochem, Inc. is Dr. Elazar Rabbani Ph.D., 78, who is the Co-Founder, Chairman, Chief Scientific Officer & Sec..

What's Barry Weiner's mailing address?

Barry's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK, NY, 10022.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis..., and Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of Mr. Weiner stock trades at Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer